The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $43.61

Today's change+1.04 +2.43%
Updated July 20 2:57 PM EDT. Delayed by at least 15 minutes.
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $43.61

Today's change+1.04 +2.43%
Updated July 20 2:57 PM EDT. Delayed by at least 15 minutes.

Novo Nordisk A/S crosses above 20-day moving average

Novo Nordisk A/S is up sharply today, rallying (U.S.)$1.04 or 2.43% to (U.S.)$43.61 and crossing above its 20-day moving average. Over the last five days, shares have gained 2.34% and 21.60% year to date. Shares have underperformed the S&P 500 by 35.07% during the last year.

Key company metrics

  • Open(U.S.) $43.07
  • Previous close(U.S.) $42.57
  • High(U.S.) $43.71
  • Low(U.S.) $43.07
  • Bid / Ask(U.S.) $43.60 / (U.S.) $43.61
  • YTD % change+21.60%
  • Volume1,358,309
  • Average volume (10-day)1,349,338
  • Average volume (1-month)1,667,499
  • Average volume (3-month)2,070,216
  • 52-week range(U.S.) $30.89 to (U.S.) $57.41
  • Beta0.63
  • Trailing P/E18.38×
  • P/E 1 year forward19.44×
  • Forward PEG2.05×
  • Indicated annual dividend(U.S.) $1.34
  • Dividend yield3.07%
  • Trailing EPS(U.S.) $2.37
Updated July 20 2:57 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+34.18%

Based on its net profit margin of 34.18%, Novo Nordisk A/S is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.22%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue28,45229,57227,53727,459
Total other revenue--------
Total revenue28,45229,57227,53727,459
Gross profit24,20124,65423,55123,414
Total cost of revenue4,2514,9183,9864,045
Total operating expense14,96218,36615,11714,962
Selling / general / administrative7,7009,0757,8757,740
Research & development3,2894,4703,4583,331
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)----00
Other operating expenses, total-278-97-202-154
Operating income13,49011,20612,42012,497
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax13,00410,94212,30112,602
Income after tax10,1568,6999,8039,968
Income tax, total2,8482,2432,4982,634
Net income10,1568,6999,8039,968
Total adjustments to net income--------
Net income before extra. items10,1568,6999,8039,968
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items10,1568,6999,8039,968
Inc. avail. to common incl. extra. items10,1568,6999,8039,968
Diluted net income10,1568,6999,8039,968
Dilution adjustment00--0
Diluted weighted average shares2,5002,5172,5312,541
Diluted EPS excluding extraordinary itemsvalue per share4.063.463.873.92
Dividends per sharevalue per share0.006.770.000.00
Diluted normalized EPSvalue per share4.063.463.873.92